Form 4: RenovoRx VP, Controller and PAO Ron Kocak Granted Incentive Stock Options

Ron Kocak, VP, Controller and PAO of RenovoRx, Inc., was granted incentive stock options to purchase 166,400 shares of the company's common stock on April 14, 2025.

Summary

• On April 14, 2025, Ron Kocak, VP, Controller and PAO of RenovoRx, Inc., was granted an incentive stock option.
• The option allows him to purchase up to 166,400 shares of the company's common stock at an exercise price of $0.8448 per share.
• The options vest over four years, starting January 1, 2025, at a rate of 1/48 per month, with no cliff vesting.
• The option will only become exercisable when there is an effective registration statement covering the shares underlying the option.
• The option will be fully vested by January 1, 2029, and will expire on April 14, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation practice. The positive aspect is aligning executive interests with shareholders, but there's also the risk associated with the stock's future performance.

Positives

• Granting stock options can align the interests of the executive with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The option is not exercisable until a registration statement is effective, which introduces uncertainty.
• The value of the options depends on the future performance of the company's stock.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the stock options.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• The size of the grant (166,400 shares) and the vesting schedule (four years) would need to be compared to similar companies of RenovoRx's size and stage to determine if it is in line with industry norms.
• Companies like Geron Corporation and Athersys often use stock options as part of their compensation strategy.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive.
• Employees may see this as a sign of confidence in the company's future.

Key Dates

Keywords

stock options, incentive stock option, RenovoRx, RNXT, Ron Kocak, executive compensation, Form 4, beneficial ownership